HDAC9 and breast cancer: Some of the more promising combinations have been HDAC inhibition combined with aromatase inhibition in HR+ER− breast cancer, HDAC inhibition plus EGFR inhibition in non-small cell lung cancer, and HDAC inhibitors with checkpoint inhibitor treatment in colorectal cancer.